Moreover, in the present study the integrated diagnosis using RNA-seq was useful for clinical management, especially for determining chemotherapy regimens, in some of the recently diagnosed patients, including those diagnosed with SMARCA4-deficient undifferentiated sarcoma, NUT carcinoma, alveolar rhabdomyosarcoma, and synovial sarcoma. Here, SMARCA4 is linked to undifferentiated (embryonal) sarcoma.